IBRX has been granted a new patent
Jan 15, 2025, 11:35 PM
38.91%
What does IBRX do
ImmunityBio is a San Diego-based clinical stage immunotherapy company with 628 employees, focusing on therapies for urologic cancers and infectious diseases. Its lead product candidate, Anktiva, is an IL-15 superagonist fusion protein.
IBRX filed a patent for "ex vivo generation of immune effector cells from apheresis material intermediates" on Wed, July 5, 2023.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.